NAS casts off non-therapeutic business
This article was originally published in Clinica
Executive Summary
Cancer therapy specialist North American Scientific (NAS) has definitively agreed to divest its non-therapeutic product line – consisting of radiation sources used for calibration, measurement, analysis and control applications – to the US subsidiary of German company Eckert & Ziegler Isotope Products. The transaction, expected to close tomorrow, is valued at around $6m. The sale will enable Chatsworth, California-based NAS to focus on its cancer therapy business, which includes its Prospera and ClearPath brachytherapy product lines for prostate and breast cancers.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.